What pharmacologic treatments are recommended for managing self‑injurious behavior?

Medication Treatment for Self-Injurious Behaviors

For self-injurious behavior in individuals with intellectual disability, atypical antipsychotics (particularly risperidone) are the first-line pharmacological intervention, with naltrexone as an alternative when self-injury persists despite initial treatment.

Primary Pharmacological Approach

Atypical Antipsychotics (First-Line)

Atypical antipsychotics should be the initial medication choice for managing self-injurious behavior, particularly in individuals with intellectual disability 1, 2, 3. The evidence shows:

• Risperidone is specifically recommended with starting dose of 0.25 mg at bedtime, maximum 2-3 mg daily in divided doses 4
• Atypical antipsychotics probably produce a large reduction in self-injury (SMD -1.43), though this is based on limited data 3
• These agents are preferred over typical antipsychotics due to lower risk of extrapyramidal symptoms and tardive dyskinesia 4, 1

Alternative atypical antipsychotics if risperidone is not tolerated 4:

• Olanzapine: Start 2.5 mg at bedtime, maximum 10 mg daily; generally well-tolerated and effective for aggression and self-injury 4, 5
• Aripiprazole: Preferred in children/adolescents with intellectual disability due to lower metabolic side effects 1

Important Caveats for Antipsychotics

The evidence base has significant limitations. Most antipsychotic trials show increased risk of metabolic adverse effects (weight gain, increased appetite) and neurological adverse effects (sedation, fatigue) 3. Monitor weight, metabolic parameters, and movement disorders closely. Avoid typical antipsychotics (haloperidol, fluphenazine) as first-line due to 50% risk of tardive dyskinesia after 2 years in elderly patients 4.

Alternative Pharmacological Options

Naltrexone (Opiate Antagonist)

Naltrexone should be considered when atypical antipsychotics fail or are not tolerated 6, 7, 8. The evidence shows:

• Doses of 25-50 mg produce statistically significant decreases in self-injury 6
• Particularly effective when self-injury has an addictive or self-stimulatory quality 7
• Generally well-tolerated with minimal adverse effects 6

However, the evidence is weak—only small trials with high risk of bias and short follow-up periods 6. One trial found no therapeutic effect, highlighting inconsistent efficacy 6.

Mood Stabilizers (Second-Line for Agitation)

When self-injury occurs in context of severe agitation, mood instability, or bipolar symptoms 4:

• Divalproex sodium (Depakote): Start 125 mg twice daily, titrate to therapeutic level (40-90 mcg/mL); better tolerated than other mood stabilizers 4
• Carbamazepine: 100 mg twice daily, titrate to 4-8 mcg/mL; monitor CBC and liver enzymes due to problematic side effects 4

SSRIs (For Comorbid Conditions)

SSRIs are NOT first-line for self-injury itself but should be considered when self-injury occurs with comorbid depression or anxiety 1, 7:

• Fluoxetine or sertraline are treatment of choice in children/adolescents with intellectual disability 1
• Serotonergic agents show promise given serotonin's role in self-injury pathophysiology 7
• No direct evidence for reducing self-injury as primary outcome 3

Critical Clinical Algorithm

Step 1: Identify underlying psychiatric disorder—self-injury is a symptom, not a diagnosis 1. Prescribing for behavior alone should be minimized unless risk of injury is severe 1.

Step 2: Start risperidone 0.25 mg at bedtime, increase slowly every 5-7 days to maximum 2-3 mg daily 4. Monitor for sedation, weight gain, and extrapyramidal symptoms.

Step 3: If inadequate response after 4-8 weeks at therapeutic dose, consider:

• Switching to olanzapine or aripiprazole 4, 1
• Adding naltrexone 25-50 mg daily 6

Step 4: If self-injury occurs with severe agitation/mood instability, add divalproex sodium 4.

Step 5: Avoid benzodiazepines for chronic management—10% risk of paradoxical agitation and potential for disinhibition in intellectual disability population 4, 1.

Common Pitfalls to Avoid

• Do not use medication as substitute for appropriate behavioral interventions and services 1—pharmacotherapy should be part of comprehensive treatment plan
• Avoid polypharmacy unless absolutely necessary 2—single agent preferred
• Do not continue ineffective medication indefinitely—reassess after adequate trial (4-8 weeks minimum) 4
• Monitor for behavioral activation or worsening when starting any psychotropic, particularly in context of unrecognized bipolar disorder 9

Monitoring Requirements

• Metabolic monitoring: Weight, glucose, lipids at baseline and regularly with atypical antipsychotics 3
• Movement disorder assessment: Regular evaluation for extrapyramidal symptoms and tardive dyskinesia 4
• Liver function and CBC: Required with mood stabilizers 4
• Behavioral tracking: Use quantitative measures to assess treatment response 1

The evidence for pharmacological treatment of self-injury remains limited with small effect sizes across all interventions 2, 3. Non-pharmacological interventions should be prioritized initially per NICE guidelines 2, with medication reserved for severe risk of harm or when behavioral interventions fail.